CLOs on the Move

Intercept Pharmaceuticals

www.interceptpharma.com

 
We are a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive, non-viral liver diseases, including primary biliary cholangitis (PBC), nonalcoholic steatohepatitis (NASH), primary sclerosing cholangitis (PSC) and biliary atresia. In a new age of liver disease treatment, our team is developing vital therapies to meet the needs of those living with progressive, non-viral liver disease. We are committed to improving patients` lives and addressing the liver community`s most pressing needs. Our corporate headquarters is located in New York, and we have additional offices in San Diego, London and Perugia.
  • Number of Employees: 250-1000
  • Annual Revenue: $250-500 Million

Executives

Name Title Contact Details
Jaimee Reid
Head of Legal Compliance Profile
Edward Mahaney-Walter
Associate General Counsel Profile
Ingrid Delaet
Vice President Regulatory Affairs Profile
Jared Freedberg
General Counsel and Secretary Profile

Jobs

Director, Human Resources

Intercept Pharmaceuticals San Diego, CA
Accountable for developing and implementing U.S. Regional (San Diego office) HR strategy, in alignment with global HR direction & strategy, to ensure delivery of HR support that enables the U.S. organization to meet or exceed short- and long-term business objectives. While partnering closely with U.S. business operations leaders, areas of ...

Similar Companies

Global Medical Institutes

Global Medical Institutes is a Princeton, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Assertio Therapeutics

Assertio Therapeutics, Inc. is an American specialty pharmaceutical company.

Santaris Pharma A/S USA

Santaris Pharma A/S USA is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

AcariaHealth

AcariaHealth is a Orlando, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Olema

Olema is a preclinical biotechnology company developing new drugs for the treatment and prevention of estrogen receptor (ER) positive breast cancer. At Olema we leverage the exquisite knowledge of the molecular action of the ER to design compounds that are superior to both the current drugs and those in development.